Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples